Source: http://moviesblog.mtv.com/2013/04/16/steve-carell-anchorman-2-pretty-good/
ncaa final four Evil Dead halle berry kurt cobain Kamala Harris URI Facebook Home
Tuesday, April 16, 2013
Steve Carell Enthusiastically Endorses 'Anchorman 2': 'It's Pretty Good'
In the few weeks that "Anchorman: The Legend Continues" has been filming in Atlanta, the actors have been tight-lipped on what exactly will happen when Ron Burgundy and the Channel 4 News Team reassemble this December. Things weren't any different on Sunday at the 2013 MTV Movie Awards when MTV News' Josh Horowitz got a [...]
Monday, April 15, 2013
Mom on bus caught on cell phone video: 'I didn't toss my baby'
By Debra Bogstie, NBCConnecticut.com
A mother caught on cell phone video apparently throwing her baby across the aisle of a bus, prompting a police investigation, says she didn't do it.
"I didn't toss my baby. I set her down," said the woman when NBC Connecticut confronted her at her Hartford home.
The startling scene was caught on tape by a concerned passenger during a bus ride on Albany Avenue Wednesday morning. It's since gone viral with internet postings on YouTube, Facebook, and elsewhere.
The two minute video shows a woman screaming obscenities at another passenger, as her baby sits on her lap at times holding her little ears.
The woman repeatedly asks other passengers to take her child so she can fight the woman. "I will thrash you. Somebody grab my baby. I'm going to beat the... of you on this bus," she's heard saying in the video. Then, it gets worse.
The woman is seen throwing the baby across the aisle into the arms of another passenger. Then, she heads up front and gets into a fist fight.
Read more stories on NBCConnecticut.com
The bus driver pulled over to the side of the road and opened the doors, according to CT Transit. As he called for help, the woman retrieved her baby and left the bus. So did the other passenger involved in the fight.
When NBC Connecticut arrived at her home Friday night, police and child welfare workers were inside talking to her. After they left, we knocked on the door and the woman answered.
When asked if she had any comment on the situation, the woman said, "No. Connecticut Transit, get the full video. I didn't toss my baby. Get the full video."
She then closed the door, only to open it once again.
"I never tossed my baby," she said. "Get the full video from Connecticut Transit. I didn't toss my baby. I set her down."
The video was so shocking that an NBC Connecticut viewer brought it to our attention. We asked Hartford police if they knew about it, and they launched an investigation.
Hartford police have not filed any charges in the case.
As part of their ongoing investigation, they're reviewing a second cell phone video from a different angle. The camera on board the bus was not working at the time of the incident, so there is no surveillance video available from CT Transit.
klimt bastille day breaking bad breaking bad food network star British Open 2012 bane
Analysis: U.S. companies add to "wall of worry", then may smash it
By Rodrigo Campos and Caroline Valetkevitch
NEW YORK (Reuters) - Many top U.S. companies have been cutting forecasts for their earnings at a rapid pace in recent weeks, but an analysis of historical data shows that rather than being a cause of despair it may be a reason for investor optimism.
Big companies are almost always conservative, regardless of whether business is humming along or not, but by one measurement, the first quarter has been the ugliest for corporate outlooks since 2001. Among S&P 500 companies making forecasts, 4.5 have come in below Wall Street estimates for every one above them, according to Thomson Reuters data.
Downbeat outlook announcements from companies, though, have a way of creating the conditions for big gains.
First, the share prices of the companies tend to decline. Then, Wall Street analysts often lower their own estimates in line with the corporate outlooks. Finally, having created an environment of lower expectations, many companies manage to beat the forecasts (their own and the analysts) after all when the results are announced.
"The companies are doing a very good job of guiding the analysts lower to pave the way for what I call 'manufactured earnings surprises,'" said Nick Raich, chief executive of The Earnings Scout, an independent research firm specializing in earnings trends, in Cleveland, Ohio. "That's the way the earnings game is played."
S&P 500 earnings were expected to increase just 1.5 percent for the first quarter when earnings season began and the latest estimate stands at 1.1 percent. But investors and strategists say that earnings will more than likely look substantially better when the season comes to a close.
So far there have been 108 warnings for first-quarter results. The 4.5-to-1 negative-to-positive ratio is the seventh worst for any quarter since 1996. Yet four of the previous six of those dire warnings periods have been followed by quarterly gains in the S&P 500; the average gain for those four with gains is 6.68 percent while the average gain for all six periods is a much lower 0.6 percent.
A 6.68 percent gain this quarter would take the S&P 500 <.spx><.inx> to 1,674 by the end of June, extending a rally that has already taken it to record highs.
A look at a greater sample shows the persistence of this pattern. Of the 20 quarters with the most negative ratios since 1996, the average gain in the S&P 500 in the following quarter was 2.3 percent. By comparison, the average move for all of the past 68 quarters dating back to 1996 is 1.7 percent.
It is in the best interest of companies to avoid disappointments. Warnings have outnumbered positive pre-announcements in all but five of those 68 quarters, and yet companies almost always report results above analysts' expectations.
The last time earnings have fallen short of analysts' forecast was the fourth quarter of 2008 was when the impact of the financial crisis was so sudden and severe that it took time for everyone to assess its depth.
In the last 16 quarters, in all but one, the analysts' expectations at the beginning of earnings season have been exceeded by anywhere from one to 22 percentage points, with an average difference of 6.4 points.
On average, 63 percent of companies beat earnings estimates, according to Reuters data going back to 1994. Investors have come to anticipate this, and recent gains may be in part due to the belief that earnings, once again, will not be as dire as forecast.
"The buy-side takes sell-side analysts with more than a grain of salt," said John Manley, chief equity strategist for Wells Fargo Advantage Funds in New York. "I don't think anybody's being fooled who doesn't want to be fooled."
This time, Wall Street analysts may be cottoning on to the usual move by companies to lower earnings expectations. Analysts have not been reducing forecasts at the same pace as the companies themselves.
"There's been a kind of a decoupling," said Dan Suzuki, U.S. equity strategist at Bank of America-Merrill Lynch in New York. However, Suzuki wrote in a note last week that changes in management forecasts tend to precede analyst revisions, so the outlook could theoretically worsen.
Full-year S&P 500 earnings are expected to hit a 2013 record of $111.62, based on an aggregate measurement of analysts' forecasts of earnings per share for the companies in the index, surpassing last year's record of $103.80, according to Thomson Reuters data.
CONSUMER COMPANIES SUFFER
This time around, consumer companies sound among the most depressed, blaming increased U.S. tax rates and ongoing weakness in Europe for lowered forecasts.
Consumer discretionary stocks currently have a negative-to-positive pre-announcement ratio of 6.5 to 1, Thomson Reuters data shows.
More than half of the roughly 30 corporate outlooks in the consumer discretionary sector are warnings from retailers, which analysts said could be the result of the higher U.S. payroll tax, a delay in income tax refunds and other recent U.S. fiscal policy changes, such as automatic spending cuts known as sequestration.
"In essence, we've had a tightening of fiscal policy which includes the sequester but also includes tax rate increases," said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama.
Target
A number of companies, including some airlines and other travel-related businesses, have said they have been hit by the U.S. government spending cuts. Delta Airlines
(Reporting by Rodrigo Campos and Caroline Valetkevitch, editing by David Gaffen and Martin Howell and Theodore d'Afflisio)
Source: http://news.yahoo.com/analysis-u-companies-add-wall-worry-then-may-210419727--sector.html
hilary duff michigan state michigan state andrew luck pro day josh johnson kim kardashian flour matt forte
Sunday, April 14, 2013
Maine Public Employees commits to real estate fund - Pensions ...
Sorry, Readability was unable to parse this page for content.
Django Unchained jennifer hudson jennifer garner jennifer garner daytona 500 national margarita day Ronda Rousey
Could new flu spark global flu pandemic? New bird flu strain seen adapting to mammals, humans
Apr. 12, 2013 ? A genetic analysis of the avian flu virus responsible for at least nine human deaths in China portrays a virus evolving to adapt to human cells, raising concern about its potential to spark a new global flu pandemic.
The collaborative study, conducted by a group led by Masato Tashiro of the Influenza Virus Research Center, National Institute of Infectious Diseases, and Yoshihiro Kawaoka of the University of Wisconsin-Madison and the University of Tokyo, appears in the current edition (April 11, 2013) of the journal Eurosurveillance. The group examined the genetic sequences of H7N9 isolates from four of the pathogen's human victims as well as samples derived from birds and the environs of a Shanghai market.
"The human isolates, but not the avian and environmental ones, have a protein mutation that allows for efficient growth in human cells and that also allows them to grow at a temperature that corresponds to the upper respiratory tract of humans, which is lower than you find in birds," says Kawaoka, a leading expert on avian influenza.
The findings, drawn from genetic sequences deposited by Chinese researchers into an international database, provide some of the first molecular clues about a worrisome new strain of bird flu, the first human cases of which were reported on March 31 by the Chinese Center for Disease Control and Prevention. So far, the new virus has sickened at least 33 people, killing nine. Although it is too early to predict its potential to cause a pandemic, signs that the virus is adapting to mammalian and, in particular, human hosts are unmistakable, says Kawaoka.
Access to the genetic information in the viruses, he adds, is necessary for understanding how the virus is evolving and for developing a candidate vaccine to prevent infection.
Influenza virus depends on its ability to attach to and commandeer the living cells of its host to replicate and spread efficiently. Avian influenza rarely infects humans, but can sometimes adapt to people, posing a significant risk to human health.
"These viruses possess several characteristic features of mammalian influenza viruses, which likely contribute to their ability to infect humans and raise concerns regarding their pandemic potential," Kawaoka and his colleagues conclude in the Eurosurveillance report.
Kawaoka, a faculty member in the UW-Madison School of Veterinary Medicine who also holds a faculty appointment at the University of Tokyo, explains that the majority of the viruses in the study -- from both humans and birds -- display mutations in the surface protein hemagglutinin, which the pathogen uses to bind to host cells. Those mutations, according to Kawaoka, allowed them to easily infect human cells.
In addition, the isolates from patients contained another mutation that allows the virus to efficiently replicate inside human cells. The same mutation, Kawaoka notes, lets the avian virus thrive in the cooler temperatures of the human upper respiratory system. It is in the cells of the nose and throat that flu typically gains a hold in a mammalian or human host.
Kawaoka and his colleagues also assessed the response of the new strain to drugs used to treat influenza, discovering that one class of commonly used antiviral drugs, ion channel inhibitors which effectively bottle up the virus in the cell, would not be effective; the new strain could be treated with another clinically relevant antiviral drug, oseltamivir.
In addition to Kawaoka and Tashiro, co-authors of the Eurosurveillance report include Tsutomu Kageyama, Seiichiro Fujisaki, Emi Takashita, Hong Xu, Shinya Yamada, Yuko Uchida, Gabriele Neumann and Takehiko Saito. The work was supported by Grants-in-Aid for Pandemic Influenza Research and Grant-in-Aid for Specially Promoted Research from the Ministry of Health, Labour and Welfare, Japan; by the NIAID Center for Research on Influenza Pathogenesis (CRIP, HHSN266200700010C); by a Grant-in-Aid for Specially Promoted Research, by the Japan Initiative for Global Research Network on Infectious Diseases from the Ministry of Education, Culture, Sports, Science, and Technology, Japan; and by ERATO, Japan.
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by University of Wisconsin-Madison. The original article was written by Terry Devitt.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Journal Reference:
- Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, Uchida Y, Neumann G, Saito T, Kawaoka Y, Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Eurosurveillance, 2013; [link]
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/6D3PTlyJgDU/130412192402.htm
Kendrick Lamar JJ Abrams New Orleans Pelicans chris brown hillary clinton apple stock Pro Bowl 2013
Tuesday, April 9, 2013
The Navy's Next Gen Fighter Jets Will Heal Themselves
PacSun apple store bestbuy bestbuy gamestop black friday deals Sephora
Monday, April 8, 2013
First trial to investigate magic mushrooms as a treatment for depression delayed by UK and EU regulations
Apr. 5, 2013 ? The world's first clinical trial to explore the use of the hallucinogenic ingredient in magic mushrooms to treat depression is being delayed due to the UK and EU rules on the use of illegal drugs in research.
Professor David Nutt, president of the British Neuroscience Association and Professor of Neuropsychopharmacology at Imperial College London (UK), will tell the BNA's Festival of Neuroscience today (Sunday) that although the UK's Medical Research Council has awarded a grant for the trial, the Government's regulations controlling the licensing of illegal drugs in research and the EU's guidelines on Good Manufacturing Practice (GMP) have stalled the start of the trial, which was expected to start this year. He is calling for a change to the regulations.
He will tell the meeting at the Barbican in London, that his research has shown that psilocybin, the psychedelic ingredient in magic mushrooms, has the potential to alleviate severe forms of depression in people who have failed to respond fully to other anti-depressant treatments. However, psilocybin is illegal in the UK; the United Nations 1971 Convention on Psychotropic Substances classifies it as a Schedule 1 drug, one that has a high potential for abuse with no recognised medical use, and the UK has classified it as a Class A drug, the classification used for the most dangerous drugs. This means that a special licence has to be obtained to use magic mushrooms in research in the UK, and the manufacture of a synthetic form of psilocybin for use in patients is tightly controlled by EU regulations.
Prof Nutt will say: "The law for the control of drugs like psilocybin as a Schedule 1 Class A drug makes it almost impossible to use them for research and the reason we haven't started the study is because finding companies who could manufacture the drug and who are prepared to go through the regulatory hoops to get the licence, which can take up to a year and triple the price, is proving very difficult. The whole situation is bedevilled by this primitive, old-fashioned attitude that Schedule 1 drugs could never have therapeutic potential, and so they have to be made impossible to access."
"The knock-on effect is this profound impairment of research. We are the first people ever to have done a psilocybin study in the UK, but we are still hunting for a company that can manufacture the drug to GMP standards for the clinical trial, even though we've been trying for a year to find one. We live in a world of insanity in terms of regulating drugs at present. The whole field is so bogged down by these intransient regulations, so that even if you have a good idea, you may never get it into the clinic."
He will say that the regulations need to be changed. "Even if I do this study and I show it's a really useful treatment for some people with depression, there's only four hospitals in this country that have a licence to hold this drug, so you couldn't roll out the treatment if it worked because the regulations would make it difficult to use," he said.
Prof Nutt and his team at Imperial College London (UK) have shown that when healthy volunteers are injected with psilocybin, the drug switched off a front part of the brain called the anterior cingulate cortex, which is known from previous imaging studies to be over-active in depression. "We found that, even in normal people, the more that part of the brain was switched off under the influence of the drug, the better they felt two weeks later. So there was a relationship between that transient switching off of the brain circuit and their subsequent mood," he will explain. "This is the basis on which we want to run the trial, because this is what you want to do in depression: you want to switch off that over-active part of the brain.
"The other thing we discovered is that the major site of action of the magic mushrooms is to turn down a circuit in the brain called the 'default mode network', which the anterior cingulate cortex is part of. The default mode network is a part of the brain between the front and back. It is active when you are thinking about you; it coordinates the thinking and emotional aspects of you."
The researchers discovered that the 'default mode network' had the highest density of 5HT2A receptors in the brain. These are known to be involved in depression and are the targets for a number of existing anti-depressive drugs that aim to improve levels of serotonin -- the neurotransmitter [1] that gives people a sense of well-being and happiness. Psilocybin also acts on these receptors.
"We have found that people with depression have over-active default mode networks, and they are continually locked into a mode of thinking about themselves. So they ruminate on themselves, on their incompetencies, on their badness, that they're worthless, that they've failed; these things are not true, and sometimes they reach delusional levels. This negative rumination may be due to a lack of serotonin and what psilocybin is doing is going in and rapidly replacing the missing serotonin, switching them back into a mind state where they are less ruminating and less depressed," Prof Nutt will say.
The proposed trial will be for patients with depression who have failed two previous treatments for the condition. Thirty patients will be given a synthetic form of psilocybin and 30 patients will be given a placebo. The drug (or placebo) will be given during two, possibly three, carefully controlled and prepared 30-60 minute sessions. The first session will be a low dose to check there are no adverse responses, the second session will give a higher, therapeutic dose, and then patients can have a third, booster dose in a later session if it's considered necessary. While they are under the influence of the drug, the patients will have guided talking therapy to enable them to explore their negative thinking and issues that are troubling them. The doctors will follow up the patients for at least a year.
"What we are trying to do is to tap into the reservoir of under-researched 'illegal' drugs to see if we can find new and beneficial uses for them in people whose lives are often severely affected by illnesses such as depression. The current legislation is stopping the benefits of these drugs being explored and for the last 40 years we have missed really interesting opportunities to help patients."
Ethical approval for the trial was granted in March and Prof Nutt says he hopes to be able to start the trial within the next six months -- so long as he can find a manufacturer for the drug.
[1] Neurotransmitters are chemicals that transmit signals from neurons (nerve cells) to target cells.
[2] Funding: The Beckley Foundation has funded part of Prof Nutt's research, and the Medical Research Council has agreed a grant for the proposed clinical trial.
Abstract title: "Can we use psychedelic drugs to treat depressions?" Symposium: "Treating depression with antidepressants: where are we now and where are we going?"
Share this story on Facebook, Twitter, and Google:
Other social bookmarking and sharing tools:
Story Source:
The above story is reprinted from materials provided by British Neuroscience Association, via AlphaGalileo.
Note: Materials may be edited for content and length. For further information, please contact the source cited above.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
chicago cubs split pea soup recipe the client list yahoo.com/mail baylor april 9 albatross
Syria activists say 20 killed in army airstrikes
AMMAN, Jordan (AP) ? Syrian government airstrikes killed at least 20 people as the army pressed ahead Sunday with its campaign to crush the rebellion against President Bashar Assad, activists said.
State television said the primary goal of the airstrikes was to "recapture areas taken by the terrorists," a reference to the rebel Free Syrian Army, who took up arms against Assad after security forces launched a bloody crackdown on protesters two years ago.
The rebels control large swaths of northern Syria, and captured their first provincial capital ? the city of Raqqa ? last month. They have also been making gains in recent weeks in the south, seizing military bases and towns in the strategically important region between Damascus and the border with Jordan, about 160 kilometers (100 miles) from the capital Damascus.
The Britain-based Syrian Observatory for Human Rights says Sunday's airstrikes targeted the northern cities of Aleppo, Homs, Hama, Idlib, the western Mediterranean city of Latakia, the eastern province of Deir el-Zour and the suburbs of Damascus.
To the south in Daraa, a man was shot dead by an army sniper, the Observatory said. It added that there was little rebel advancement in the province where opposition forces seized large swathes of land over the past two weeks.
?In the outskirts of Damascus, the army pursued rebels in Adra district and raided their base in the neighborhood of Qarra, the state news agency SANA reported.
It also said the army "demolished two dens with all terrorists and ammunition inside them in al-Khalidiya district in the central province of Homs, killing several terrorists." It provided no other details.
In a rare move, the government urged rebels to surrender their arms, warning in cell phone text messages that the army is "coming to get you."
Source: http://news.yahoo.com/syria-activists-20-killed-army-airstrikes-121644030.html
McKillen puts pressure on Department of Finance as he attempts to ...
Funny how Minister for Finance Michael Noonan and his Department of Finance resign themselves to being ?powerless? onlookers towards the banks in which they have controlling or substantial interests, when challenged by the Opposition, but as revealed in the Irish Sunday press today, they are portrayed as assuming the role of power-broker when contacted by billionaires.
Both the Sunday Times, which is embroiled in an injunction row at present with developer and businessman Paddy McKillen, and the Sunday Independent today report on contact between representatives of the billionaire Barclay twins and the Department of Finance. The Barclay twins are vigorously pursuing control of the three Maybourne hotels in central London, Claridge?s, the Berkeley and the Connaught; Paddy McKillen owns 36% of the company controlling the hotels, the Barclays own 28% and there is a tussle before the British appeal court at present about control of Derek Quinlan?s 36%.
Central to today?s storm-in-a-teacup/controversy are emails in October 2011 when the Barclays were intensively pursuing the stakes of both the Green family and Derek Quinlan. The Barclays were also sniffing around Paddy McKillen?s loans at Anglo, or Irish Bank Resolution Corporation.? John Moran ? who is now the Secretary General at the Department of Finance, but was in late 2011 Head of Banking at the Department reporting directly to its then Secretary General, Kevin Cardiff ? is cast as facilitating the Barclays by telling their representative Richard Faber in an email that if he was ?not making the right progress for whatever reason with the IBRC? then senior Department of Finance mandarins ?remain at your disposal (as of course do I if you are unable to reach them)?
Paddy has gotten hold of Department of Finance emails under Freedom of Information requests and is predictably unhappy, though there is something of the pot and kettle here, with Paddy having previously written to An Taoiseach and others in government in May 2011, making representations to stop his loans being acquired by NAMA. Minister Noonan said his office passed those representations on to NAMA, which subsequently decided not to acquire Paddy?s loans. So here you have Paddy in May 2011 making his own representations to government, but when the Barclays do something similar six months later, Paddy starts whinging.
Paddy?s spokeswoman is quoted as saying ?Mr McKillen is demanding a full explanation from the Department of Finance regarding what appear to be informal, supportive communications between the department? and the Barclays. Paddy is reportedly unhappy with the Department staff and is making noises about breaches of the Ethics in Public Office legislation.
There is a claim reported arising from ?sources? that if IBRC had sold Paddy?s loans to the Barclays then the Irish taxpayer would have faced multi ?100m losses. I would take that claim with a giant pinch of salt, and indeed it remains curiously unclear why IBRC didn?t progress talks with the Barclays on Paddy?s loans ? which are a gateway to control over Paddy?s shares in the hotels ? because ultimately, IBRC could have made the sale of any of Paddy?s loans conditional on the buyer buying ALL of Paddy?s loans at par value. The tax payer could have been in clover if a deal had been done on the right loans at the right price.
For once, there is sympathy on here for John Moran. He is being hounded by the Sindo at home and on his mobile for comment ? don?t be surprised John, if the Sindo feature your family life next week. After all, John received communication from a serious buyer wanting to buy Irish state assets ? loans at IBRC which was 100% owned by the Government are ?state assets? ? and he seems to have responded in a helpful and facilitating manner, though there is nothing in the emails which suggest shenanigans. What was he supposed to have written? There is actually some relief on here that John recognized the Barclays were serious buyers, and that he did promptly pass on messages to IBRC, and he treated the Barclays with courtesy.
By the way, just around now, Paddy McKillen should be in intensive talks with the special liquidator at IBRC about refinancing his estimated ?300m personal and ?550m corporate loans, which will otherwise be offered for sale and the Barclay brothers have let it be known that they may be prepared to offer a premium for those loans above their market value. Paddy made the Freedom of Information request on 8th?March 2013, a month after the announcement of the IBRC liquidation and when it became clear that loans would be offered for refinancing before being offered for sale on the open market. So, here you have the Department of Finance coming under pressure from Paddy with threats of referrals under the Ethics in Public Office legislation at the same time as IBRC is considering refinancing proposals. Normally liquidators are independent and protect the rights of all creditors, but the IBRC liquidation is ?special? and Minister Noonan and the Department of Finance control the liquidation through the IBRC liquidation Act. All a coincidence, no doubt.
benjamin netanyahu storm shelters nick lachey chevy volt christina hendricks lifelock camp david
Saturday, April 6, 2013
Kirsten Gagnaire: Maternal Alliance for Maternal Health South Africa -- Panashe Chipikiri
This post is part of the Global Mom Relay. Every time you share this blog, $5 will go to women and girls around the world. Scroll to the bottom to find out more.
In Johannesburg, women living in poverty face many challenges, which include getting access to high quality healthcare. Hillbrow, a community in Johannesburg, has one of the highest incidences of HIV, unemployment and poverty. HIV prevalence in this community is estimated at 30 percent among pregnant women. Despite the challenges of living in a HIV prevalent community, more new and expectant mothers are getting access to evidence based vital health information in the palms of their hands through the Mobile Alliance for Maternal Action (MAMA). MAMA works in South Africa to help more mothers get access to culturally sensitive health information via mobile phones to better care for themselves and their babies.
Mothers like Panashe Chipikiri, 23, began using MAMA South Africa's mobile web tool -- askmama.mobi -- to guide her through the stages of her pregnancy and her baby's first year. Askmama.mobi is an interactive site that delivers content based on a mother's due date or age of her baby. The mobi site is just one of the five tools that MAMA South Africa provides mothers, in addition to SMS and voice messages, USSD (an interactive question and answer service), and soon through MXit, a social networking site popular in South Africa.
"I joined when I was pregnant. They [MAMA] told me what to put in my bag, the danger signs to rush to the hospital, so I didn't have any problems when I was delivering," said Panashe.
In addition to encouraging and empowering mothers with stage-based health information, MAMA's mobile messages provide reminders for mothers to go to the clinic. For mothers living with HIV, MAMA provides messages on the importance of taking ARV (Antiretroviral), breastfeeding, and getting their baby tested for HIV. While each mother has a different story, Panashe's story is an example of a mom, who continues to take better care of herself and her baby by having the power of health in her hand through MAMA.
MAMA South Africa has a goal of reaching 500,000 mothers by 2015. Click here to see the askmama.mobi site.
Each time you share this Global Mom Relay piece on Facebook, Twitter, or Email, or donate $5 or more through clicking on the above graphic, a $5 donation (up to $62,500 per week or $125,000 every two weeks) will be donated by Johnson & Johnson and the Bill & Melinda Gates Foundation to the Mobile Alliance for Maternal Health (MAMA). Join us by sharing it forward and unlock the potential for women and children around the globe. For more information, visitwww.unfoundation.org/
?
Follow Kirsten Gagnaire on Twitter: www.twitter.com/@mamaglobal
"; var coords = [-5, -72]; // display fb-bubble FloatingPrompt.embed(this, html, undefined, 'top', {fp_intersects:1, timeout_remove:2000,ignore_arrow: true, width:236, add_xy:coords, class_name: 'clear-overlay'}); });
Source: http://www.huffingtonpost.com/kirsten-gagnaire/mama-south-africa_b_3025741.html
jill biden jill biden martin luther king jr baltimore ravens ravens Ravens vs Patriots 49ers Vs Falcons
Friday, April 5, 2013
Shakira?s Main Men Practice Waiting Patiently
"Daddy and son waiting for Milan's passport!" Shakira captions this photo she Tweeted Friday of boyfriend Gerard Piqu? and their 10-week-old son.
Source: http://feeds.celebritybabies.com/~r/celebrity-babies/~3/SO79Ym6rRMw/
Michelle Jenneke batman Colorado Shooting News joe paterno British Open MC Chris Colorado shooting suspect
Subscribe to:
Posts (Atom)